Skip to main content
Top
Published in: Acta Neuropathologica Communications 1/2024

Open Access 01-12-2024 | Neuroblastoma | Research

Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion

Authors: Felipe Andreiuolo, Christina K. Ferrone, Sharika Rajan, Arie Perry, Ekin Guney, Elaine Cham, Caterina Giannini, Angus Toland, Nicholas Willard, Andrea Silveira de Souza, Karen Dazelle, Hye-Jung Chung, Omkar Singh, Kyle Conway, Nicholas Coley, Christopher Dampier, Zied Abdullaev, Drew Pratt, Patrick J. Cimino, Martha Quezado, Kenneth Aldape

Published in: Acta Neuropathologica Communications | Issue 1/2024

Login to get access

Abstract

Central nervous system (CNS) embryonal tumors are a heterogeneous group of high-grade malignancies, and the increasing clinical use of methylation profiling and next-generation sequencing has led to the identification of molecularly distinct subtypes. One proposed tumor type, CNS tumor with BRD4::LEUTX fusion, has been described. As only a few CNS tumors with BRD4::LEUTX fusions have been described, we herein characterize a cohort of 9 such cases (4 new, 5 previously published) to further describe their clinicopathologic and molecular features. We demonstrate that CNS embryonal tumor with BRD4::LEUTX fusion comprises a well-defined methylation class/cluster. We find that patients are young (4 years or younger), with large tumors at variable locations, and frequently with evidence of leptomeningeal/cerebrospinal fluid (CSF) dissemination. Histologically, tumors were highly cellular with high-grade embryonal features. Immunohistochemically, 5/5 cases showed synaptophysin and 4/5 showed OLIG2 expression, thus overlapping with CNS neuroblastoma, FOXR2-activated. DNA copy number profiles were generally flat; however, two tumors had chromosome 1q gains. No recurring genomic changes, besides the presence of the fusion, were found. The LEUTX portion of the fusion transcript was constant in all cases assessed, while the BRD4 portion varied but included a domain with proto-oncogenic activity in all cases. Two patients with clinical follow up available had tumors with excellent response to chemotherapy. Two of our patients were alive without evidence of recurrence or progression after gross total resection and chemotherapy at 16 and 33 months. One patient relapsed, and the last of our four patients died of disease one month after diagnosis. Overall, this case series provides additional evidence for this as a distinct tumor type defined by the presence of a specific fusion as well as a distinct DNA methylation signature. Studies on larger series are required to further characterize these tumors.
Appendix
Available only for authorised users
Literature
16.
go back to reference Barresi S, Giovannoni I, Rossi S, Stracuzzi A, Quacquarini D, Cafferata B, Piscitelli D, De Leonardis F, Marzullo A, Alaggio R (2021) A novel BRD4-LEUTX fusion in a pediatric sarcoma with epithelioid morphology and diffuse S100 expression. Genes Chromosom Cancer 60:647–652. https://doi.org/10.1002/gcc.22974CrossRefPubMed Barresi S, Giovannoni I, Rossi S, Stracuzzi A, Quacquarini D, Cafferata B, Piscitelli D, De Leonardis F, Marzullo A, Alaggio R (2021) A novel BRD4-LEUTX fusion in a pediatric sarcoma with epithelioid morphology and diffuse S100 expression. Genes Chromosom Cancer 60:647–652. https://​doi.​org/​10.​1002/​gcc.​22974CrossRefPubMed
28.
Metadata
Title
Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion
Authors
Felipe Andreiuolo
Christina K. Ferrone
Sharika Rajan
Arie Perry
Ekin Guney
Elaine Cham
Caterina Giannini
Angus Toland
Nicholas Willard
Andrea Silveira de Souza
Karen Dazelle
Hye-Jung Chung
Omkar Singh
Kyle Conway
Nicholas Coley
Christopher Dampier
Zied Abdullaev
Drew Pratt
Patrick J. Cimino
Martha Quezado
Kenneth Aldape
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Acta Neuropathologica Communications / Issue 1/2024
Electronic ISSN: 2051-5960
DOI
https://doi.org/10.1186/s40478-024-01746-7

Other articles of this Issue 1/2024

Acta Neuropathologica Communications 1/2024 Go to the issue